TP53 and breast cancer: The recent proof-of-principle study in which temporal heterogeneity was traced using specific mutations in PIK3CA and TP53 in cfDNA from breast cancer patients suggests that it is a viable, sensitive and real-time surrogate for tumor burden [55].